By Professor Elgene Lim

Preprints

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Abuelmaaty S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2020, VGLL1 drives therapy resistance in estrogen receptor positive breast cancer, http://dx.doi.org/10.1101/2020.11.29.402842

Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, 2020, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-62718/v1

Wu S; Roden D; Al-Eryani G; Bartonicek N; Harvey K; Cazet A; Chan C-L; Junankar S; Hui M; Millar E; Beretov J; Horvath L; Joshua A; Stricker P; Wilmott J; Quek C; Long G; Scolyer R; Yeung B; Segara D; Mak C; Warrier S; Powell J; O'Toole S; Lim E; Swarbrick A, 2020, Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis, http://dx.doi.org/10.1101/2020.06.04.135277

Wu S; Roden D; Wang C; Holliday H; Harvey K; Cazet A; Murphy K; Pereira B; Al-Eryani G; Bartonicek N; Hou R; Torpy J; Junankar S; Chan C-L; Lam E; Hui M; Gluch L; Beith J; Parker A; Robbins E; Segara D; Mak C; Cooper C; Warrier S; Forrest A; Powell J; O’Toole S; Cox T; Timpson P; Lim E; Liu S; Swarbrick A, 2020, Single-cell analysis reveals diverse stromal subsets associated with immune evasion in triple-negative breast cancer, http://dx.doi.org/10.1101/2020.06.04.135327

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, http://dx.doi.org/10.21203/rs.3.rs-16182/v2

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, http://dx.doi.org/10.21203/rs.3.rs-16182/v1

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized inBRCA1mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, http://dx.doi.org/10.1101/2020.01.29.911883

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon E; Lim E, 2020, MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer, http://dx.doi.org/10.1101/2020.06.09.140921

Cazet A; Hui M; Elsworth B; Wu S; Roden D; Chan C-L; Skhinas J; Collot R; Yang J; Harvey K; Johan Z; Cooper C; Nair R; Herrmann D; McFarland A; Deng N-T; Ruiz-Borrego M; Rojo F; Trigo J; Bezares S; Caballero R; Lim E; Timpson P; O’Toole S; Watkins N; Cox T; Samuel M; Martín M; Swarbrick A, 2017, Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer, http://dx.doi.org/10.1101/215954

Other

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Data from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.c.7585327

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Figures from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032298

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 3 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032295

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 4 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032292

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 5 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032289

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 6 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032286

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table S1 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032283

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table S2 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032280

Back to profile page